The Resource Therapeutic potential of terbinafine (Lamisil) in dermatomycoses, prepared by CCT Healthcare Communications on behalf of Sandoz Pharma Ltd. ; guest editors, Roderick J. Hay, John D. Stratigos

Therapeutic potential of terbinafine (Lamisil) in dermatomycoses, prepared by CCT Healthcare Communications on behalf of Sandoz Pharma Ltd. ; guest editors, Roderick J. Hay, John D. Stratigos

Label
Therapeutic potential of terbinafine (Lamisil) in dermatomycoses
Title
Therapeutic potential of terbinafine (Lamisil) in dermatomycoses
Statement of responsibility
prepared by CCT Healthcare Communications on behalf of Sandoz Pharma Ltd. ; guest editors, Roderick J. Hay, John D. Stratigos
Contributor
Subject
Language
eng
Member of
Cataloging source
PPC
Illustrations
illustrations
Index
no index present
Literary form
non fiction
Nature of contents
bibliography
http://library.link/vocab/relatedWorkOrContributorDate
  • 1947-
  • 1926-
  • 1991
http://library.link/vocab/relatedWorkOrContributorName
  • Hay, R. J.
  • Stratigos, John D.
  • CCT Healthcare Communications
  • European Academy of Dermatology and Venereology
Series statement
  • British journal of dermatology
  • Supplement,
Series volume
  • v. 126.
  • 39 (Feb. 1992)
http://library.link/vocab/subjectName
  • Antifungal Agents
  • Naphthalenes
Label
Therapeutic potential of terbinafine (Lamisil) in dermatomycoses, prepared by CCT Healthcare Communications on behalf of Sandoz Pharma Ltd. ; guest editors, Roderick J. Hay, John D. Stratigos
Instantiates
Publication
Note
"Based on the proceedings of a symposium, sponsored by Sandoz Pharma Ltd. at the 2nd Congress of the European Academy of Dermatology and Venereology, Athens, Greece, 10 October 1991."
Bibliography note
Includes bibliographical references
Control code
000111401
Dimensions
28 cm.
Extent
vi, 69 p.
Note
COLL. PHYSICIANS: SHELVED AND CIRCULATED AS: British journal of dermatology. Supplement 39.
Other physical details
ill. (some col.)
System control number
  • (Sirsi) 111401
  • 111575
Label
Therapeutic potential of terbinafine (Lamisil) in dermatomycoses, prepared by CCT Healthcare Communications on behalf of Sandoz Pharma Ltd. ; guest editors, Roderick J. Hay, John D. Stratigos
Publication
Note
"Based on the proceedings of a symposium, sponsored by Sandoz Pharma Ltd. at the 2nd Congress of the European Academy of Dermatology and Venereology, Athens, Greece, 10 October 1991."
Bibliography note
Includes bibliographical references
Control code
000111401
Dimensions
28 cm.
Extent
vi, 69 p.
Note
COLL. PHYSICIANS: SHELVED AND CIRCULATED AS: British journal of dermatology. Supplement 39.
Other physical details
ill. (some col.)
System control number
  • (Sirsi) 111401
  • 111575

Library Locations

    • Historical Medical LibraryBorrow it
      19 South 22nd Street, Philadelphia, PA, 19103-3097, US
      39.9532011 -75.1766375
Processing Feedback ...